Q1 FY27 results analysis · July 28, 2026

Pfizer Ltd Q1 FY27 Results Analysis: EBITDA Margin Expands 307 bps, Revenue Grows 8.3%

+6.6%PAT year on year, Rs. 204.47 Cr
Cofacto ResearchPublished July 28, 20262 min readPositive read
Quick summary

Pfizer Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 653.17 Cr (+8.31% YoY) and PAT growth of +6.63% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 28, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 653.17 Cr (+8.31% YoY)
PAT (Q1)Rs. 204.47 Cr (+6.63% YoY)
EBITDA margin37.90% (+307 bps YoY)
EPS (Q1)Rs. 44.69 (+6.63% YoY)
Market capRs. 21,630.46 Cr
CMPRs. 4,728.20

Quarter Snapshot

Q1 FY27 results showed 8.31% revenue growth and 307 bps EBITDA margin expansion, driven by cost restructuring and operating leverage. The company is debt-free with strong cash reserves. Key concerns include gross margin pressure from pricing headwinds and lack of explicit guidance.

Key Investment Insights

Key Positives

  • Revenue grew 8.31% YoY to Rs.653.17 Cr, with total expenses growing only 2.59% YoY.
  • EBITDA margin expanded 307 bps YoY to 37.90%, driven by lower employee costs and cost discipline.
  • PAT grew 6.63% YoY to Rs.204.47 Cr, with EPS at Rs.44.69.
  • Company remains debt-free with cash reserves of ~Rs.3,111 Cr (FY26).

Risk Factors

  • Gross materials cost ratio (net of inventory) increased ~173 bps YoY to 36.76% of revenue, indicating pricing headwinds from DPCO and trading mix shift.
  • Other income declined 33.24% YoY to Rs.44.84 Cr, impacting total income growth.
  • No explicit financial guidance provided for FY27, reducing visibility.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.